Medicare Patients Get GLP-1 Weight Drugs at $50
Eligible Part D beneficiaries can now access certain GLP-1 medications for weight management at $50 a month under the Bridge Program.
Updated on Nov. 6, 2026 in Weight Loss
Live Poll
Do you think GLP-1 weight-loss drugs are affordable enough for most people?
A Northwestern study found that GLP-1 receptor agonist (GLP-1RA) use rose 643% among U.S. adults without diabetes between 2017 and 2022, while average out-of-pocket costs fell. The Medicare GLP-1 Bridge Program, which lets eligible beneficiaries access certain GLP-1RAs for weight management for $50 a month, launched July 1.
Why it matters
The findings show how quickly these medications moved from diabetes care into routine weight management, and how payment structures are shifting the cost burden for patients. Access remains uneven, with some employers restricting coverage and certain states cutting Medicaid support for weight-management use due to high cost.
The Northwestern analysis tracked prescription use and payments across the 2017 to 2022 period, comparing adults with and without diabetes. Because payments were reported in nominal dollars without inflation adjustment, the reported cost changes may not reflect real-value shifts.
The players
Northwestern University
A research university whose investigators conducted the study of GLP-1 receptor agonist use and payments.
Boston University
A research university with which study author Krishnan, a medical school faculty member, is affiliated.
The details
GLP-1 receptor agonists mimic a gut hormone that slows stomach emptying and signals fullness to the brain, which is why they lower appetite and reduce weight in people taking them. Use grew sharply among adults without diabetes, while the drugs' total cost to insurers rose faster than the share paid by patients. Because patients' out-of-pocket costs fell even as total payments rose, much of the spending shifted to insurers and payers.
Timeline
2017 to 2022: The period analyzed in the Northwestern study of GLP-1RA use and payments.
July 1: The Medicare GLP-1 Bridge Program launched, allowing eligible beneficiaries to access certain GLP-1RAs for $50 a month.
2027: The Medicare GLP-1 Bridge Program is scheduled to end.
Health Landscape
GLP-1 receptor agonists were developed for type 2 diabetes and have since become a central option for obesity treatment across the U.S. population. The shift from diabetes-only prescribing to broad weight-management use is reshaping how insurers, Medicare, and state Medicaid programs decide what to cover.
If you are considering a GLP-1 receptor agonist for weight management, the Medicare Bridge Program's $50 monthly price may change what you pay if you are an eligible Part D beneficiary. Coverage still varies by employer and state, so it is worth asking your doctor and insurer what applies to your situation.
The takeaway
Medication use for weight management is expanding fast, and out-of-pocket costs are not the whole story. If you are weighing these medications, bring your coverage questions, including Bridge Program eligibility, to your physician.
What happens next
The Medicare GLP-1 Bridge Program is scheduled to run through 2027, when its coverage terms will be reassessed.
Further reading
For broader context on medication-based approaches, explore our Weight Loss coverage.
Source note: This article includes information reported by The Daily Northwestern.
Live Poll
Do you think GLP-1 weight-loss drugs are affordable enough for most people?
